3. Horn-Ross PL, Canchola AJ, Ma H, Reynolds P, Bernstein L. Hormonal factors and the risk of papillary thyroid cancer in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev 2011;20:1751-9.
[CROSSREF] [PUBMED] [PMC] [PDF]
4. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid 2013;23:103-10.
[CROSSREF] [PUBMED] [PMC]
5. Yasmeen S, Cress R, Romano PS, Xing G, Berger-Chen S, Danielsen B, et al. Thyroid cancer in pregnancy. Int J Gynaecol Obstet 2005;91:15-20.
[CROSSREF] [PUBMED] [PDF]
6. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am 2011;38:425-40.
[CROSSREF] [PUBMED] [PMC]
7. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-501.
[CROSSREF] [PUBMED]
8. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol 2010;6:1771-9.
[CROSSREF] [PUBMED] [PMC]
9. Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer 2014;21:T273-83.
[CROSSREF] [PUBMED]
10. Dong W, Zhang H, Li J, Guan H, He L, Wang Z, et al. Estrogen induces metastatic potential of papillary thyroid cancer cells through estrogen receptor α and β. Int J Endocrinol 2013;2013:941568.
[PUBMED] [PMC]
11. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol 2010;36:1067-80.
[PUBMED]
12. Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 2008;22:2085-98.
[PUBMED] [PMC]
13. Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids 2014;90:13-29.
[CROSSREF] [PUBMED] [PMC]
14. Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G, et al. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer 2014;13:137.
[CROSSREF] [PUBMED] [PMC] [PDF]
15. Dey P, Barros RP, Warner M, Strom A, Gustafsson JA. Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS. J Mol Endocrinol 2013;51:T61-74.
[CROSSREF] [PUBMED]
16. Yasar P, Ayaz G, User SD, Gupur G, Muyan M. Molecular mechanism of estrogen-estrogen receptor signaling. Reprod Med Biol 2016;16:4-20.
[CROSSREF] [PUBMED] [PMC] [PDF]
17. Huang Y, Dong W, Li J, Zhang H, Shan Z, Teng W. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma. BMC Cancer 2014;14:383.
[CROSSREF] [PUBMED] [PMC] [PDF]
18. Yi JW, Kim SJ, Kim JK, Seong CY, Yu HW, Chai YJ, et al. Upregulation of the ESR1 gene and ESR ratio (ESR1/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma: the impact of the estrogen receptor α/β expression on clinical outcomes in papillary thyroid carcinoma patients. Ann Surg Oncol 2017;24:3754-62.
[CROSSREF] [PUBMED] [PDF]
19. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010;20:33-41.
[CROSSREF] [PUBMED] [PMC]
20. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-501.
[CROSSREF] [PUBMED] [PMC]
21. Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol 2016;14:241.
[CROSSREF] [PUBMED] [PMC] [PDF]
22. Lee SE, Hwang TS, Choi YL, Kim WY, Han HS, Lim SD, et al. Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAFV600E mutation. Thyroid 2017;27:802-10.
[CROSSREF] [PUBMED]
23. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor crosstalk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002;21:4000-8.
[CROSSREF] [PUBMED] [PDF]
24. Yu L, Moore AB, Castro L, Gao X, Huynh HL, Klippel M, et al. Estrogen regulates MAPK-related genes through genomic and nongenomic interactions between IGF-I receptor tyrosine kinase and estrogen receptor-alpha signaling pathways in human uterine leiomyoma cells. J Signal Transduct 2012;2012:204236.
[CROSSREF] [PUBMED] [PMC] [PDF]
25. Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J Mol Endocrinol 2008;40:173-84.
[PUBMED] [PMC]
26. Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti RM, Limonta P. Estrogen receptor β in melanoma: from molecular insights to potential clinical utility. Front Endocrinol (Lausanne) 2016;7:140.
[CROSSREF] [PUBMED] [PMC]
27. Topi G, Ghatak S, Satapathy SR, Ehrnstrom R, Lydrup ML, Sjolander A. Combined estrogen alpha and beta receptor expression has a prognostic significance for colorectal cancer patients. Front Med (Lausanne) 2022;9:739620.
[CROSSREF] [PUBMED] [PMC]
28. Kim BA, Jee HG, Yi JW, Kim SJ, Chai YJ, Choi JY, et al. Expression profiling of a human thyroid cell line stably expressing the BRAFV600E mutation. Cancer Genomics Proteomics 2017;14:53-67.
[CROSSREF] [PUBMED] [PMC]
29. Kim M, Kim SJ, Xu Z, Ha SY, Byeon JH, Kang EJ, et al. BRAFV600E transduction of an SV40-immortalized normal human thyroid cell line induces dedifferentiated thyroid carcinogenesis in a mouse xenograft model. Thyroid 2020;30:487-500.
[CROSSREF] [PUBMED]
30. Marzagalli M, Casati L, Moretti RM, Montagnani Marelli M, Limonta P. Estrogen receptor β agonists differentially affect the growth of human melanoma cell lines. PLoS One 2015;10:e0134396.
[CROSSREF] [PUBMED] [PMC]
31. Song P, Li Y, Dong Y, Liang Y, Qu H, Qi D, et al. Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. J Exp Clin Cancer Res 2019;38:354.
[CROSSREF] [PUBMED] [PMC] [PDF]
32. Zhou HB, Carlson KE, Stossi F, Katzenellenbogen BS, Katzenellenbogen JA. Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity. Bioorg Med Chem Lett 2009;19:108-10.
[PUBMED]
33. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90.
[PUBMED] [PMC]
34. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 2009;28:2796-805.
[CROSSREF] [PUBMED] [PMC] [PDF]
35. Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol 2012;2012:306879.
[CROSSREF] [PUBMED] [PMC] [PDF]
36. Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. J Thyroid Res 2011;2011:875125.
[CROSSREF] [PUBMED] [PMC] [PDF]
37. Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, et al. BRAF inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel) 2019;11:1388.
[CROSSREF] [PUBMED] [PMC]
38. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-71.
[CROSSREF] [PUBMED] [PMC]
39. Weber CJ, Marvin M, Krekun S, Koschitzky T, Karp F, Benson M, et al. Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies. Surgery 1990;108:1065-71.
[PUBMED]
40. Hoelting T, Duh QY, Clark OH, Herfarth C. Tamoxifen antagonizes proliferation and invasion of estrogen receptornegative metastatic follicular thyroid cancer cells via protein kinase C. Cancer Lett 1996;100:89-93.
[CROSSREF] [PUBMED]
41. de Araujo LF, Soares JM Jr, Simoes RS, Calio PL, OliveiraFilho RM, Simoes Mde J, et al. Effect of conjugated equine estrogens and tamoxifen administration on thyroid gland histomorphology of the rat. Clinics (Sao Paulo) 2006;61:321-6.
[CROSSREF] [PUBMED]
42. Zidan J, Rubenstein W. Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer. Oncology 1999;56:43-5.
[CROSSREF] [PUBMED] [PDF]
43. Jiang D, Srinivasan A, Lozano G, Robbins PD. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993;8:2805-12.
[PUBMED]
44. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;54:275-83.
[CROSSREF] [PUBMED]